Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.

Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, Dumpit RF, Nelson PS, Montgomery B, McCune JS, Plymate SR, Yu EY.

PLoS One. 2018 Aug 15;13(8):e0202709. doi: 10.1371/journal.pone.0202709. eCollection 2018.

2.

A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.

Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, Dumpit RF, Nelson PS, Montgomery B, McCune JS, Plymate SR, Yu EY.

PLoS One. 2018 Jun 1;13(6):e0198389. doi: 10.1371/journal.pone.0198389. eCollection 2018. Erratum in: PLoS One. 2018 Aug 15;13(8):e0202709.

3.

MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand.

Liu G, Sprenger C, Wu PJ, Sun S, Uo T, Haugk K, Epilepsia KS, Plymate S.

Oncotarget. 2015 Jan 1;6(1):288-304.

4.

AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer.

Liu G, Sprenger C, Sun S, Epilepsia KS, Haugk K, Zhang X, Coleman I, Nelson PS, Plymate S.

Neoplasia. 2013 Sep;15(9):1009-17.

5.

A study of caloric restriction versus standard diet in overweight men with newly diagnosed prostate cancer: a randomized controlled trial.

Wright JL, Plymate S, D'Oria-Cameron A, Bain C, Haugk K, Xiao L, Lin DW, Stanford JL, McTiernan A.

Prostate. 2013 Sep;73(12):1345-51. doi: 10.1002/pros.22682. Epub 2013 Jun 15.

6.

Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.

Dean JP, Sprenger CC, Wan J, Haugk K, Ellis WJ, Lin DW, Corman JM, Dalkin BL, Mostaghel E, Nelson PS, Cohen P, Montgomery B, Plymate SR.

J Clin Endocrinol Metab. 2013 May;98(5):E820-8. doi: 10.1210/jc.2012-3856. Epub 2013 Mar 26.

7.

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR.

J Clin Invest. 2010 Aug;120(8):2715-30. doi: 10.1172/JCI41824. Epub 2010 Jul 19.

8.

Transforming Growth Factor-{beta}-Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition.

Sprenger CC, Haugk K, Sun S, Coleman I, Nelson PS, Vessella RL, Ludwig DL, Wu JD, Plymate SR.

Clin Cancer Res. 2009 Dec 15;15(24):7634-7641.

9.

Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner.

Schayek H, Haugk K, Sun S, True LD, Plymate SR, Werner H.

Clin Cancer Res. 2009 Mar 1;15(5):1558-65. doi: 10.1158/1078-0432.CCR-08-1440. Epub 2009 Feb 17.

10.

Insulin-like growth factor-I receptor blockade improves outcome in mouse model of lung injury.

Choi JE, Lee SS, Sunde DA, Huizar I, Haugk KL, Thannickal VJ, Vittal R, Plymate SR, Schnapp LM.

Am J Respir Crit Care Med. 2009 Feb 1;179(3):212-9. doi: 10.1164/rccm.200802-228OC. Epub 2008 Nov 14.

11.

An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer.

Plymate SR, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P, Montgomery RB, Ludwig DL, Wu JD.

Clin Cancer Res. 2007 Nov 1;13(21):6429-39.

12.

Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors.

Wu JD, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P, Montgomery RB, Ludwig DL, Plymate SR.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6153-60.

13.

Interaction of IGF signaling and the androgen receptor in prostate cancer progression.

Wu JD, Haugk K, Woodke L, Nelson P, Coleman I, Plymate SR.

J Cell Biochem. 2006 Oct 1;99(2):392-401. Review.

PMID:
16639715
14.

In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.

Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL, Plymate SR.

Clin Cancer Res. 2005 Apr 15;11(8):3065-74.

15.

Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer.

Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR.

J Clin Invest. 2004 Aug;114(4):560-8.

16.

Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9.

Drivdahl R, Haugk KH, Sprenger CC, Nelson PS, Tennant MK, Plymate SR.

Oncogene. 2004 Jun 3;23(26):4584-93.

PMID:
15077158
17.

Activation of pro-apoptotic p38-MAPK pathway in the prostate cancer cell line M12 expressing a truncated IGF-IR.

Wu J, Haugk K, Plymate SR.

Horm Metab Res. 2003 Nov-Dec;35(11-12):751-7.

PMID:
14710354
18.

Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1.

Plymate SR, Haugk KH, Sprenger CC, Nelson PS, Tennant MK, Zhang Y, Oberley LW, Zhong W, Drivdahl R, Oberley TD.

Oncogene. 2003 Feb 20;22(7):1024-34.

PMID:
12592389
21.

Developmental regulation of Mac25/insulin-like growth factor-binding protein-7 expression in skeletal myogenesis.

Damon SE, Haugk KL, Swisshelm K, Quinn LS.

Exp Cell Res. 1997 Nov 25;237(1):192-5.

PMID:
9417882
22.

Interleukin-15 stimulates C2 skeletal myoblast differentiation.

Quinn LS, Haugk KL, Damon SE.

Biochem Biophys Res Commun. 1997 Oct 9;239(1):6-10.

PMID:
9345260
24.

Interleukin-15: a novel anabolic cytokine for skeletal muscle.

Quinn LS, Haugk KL, Grabstein KH.

Endocrinology. 1995 Aug;136(8):3669-72.

PMID:
7628408
25.

Regulation of muscle cell proliferation by extracts from crushed muscle.

Haugk KL, Roeder RA, Garber MJ, Schelling GT.

J Anim Sci. 1995 Jul;73(7):1972-81.

PMID:
7592081
26.

The development and evaluation of a community mental health education program for seminarians.

Haugk KC, Dorr D.

Am J Community Psychol. 1976 Sep;4(3):283-92.

PMID:
970379
27.

Unique contributions of churches and clergy to community mental health.

Haugk KC.

Community Ment Health J. 1976 Spring;12(1):20-8.

PMID:
954393
28.

Pastoral care and counseling: A survey of recommended readings.

Haugk KC, Hong BA.

J Relig Health. 1975 Jan;14(1):58-62. doi: 10.1007/BF01533839. No abstract available.

PMID:
24408716

Supplemental Content

Support Center